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cardiac-type mucosa; alternatively described as a
columnar-lined esophagus with intestinal metaplasia or
Barrett’s mucosa. The clinical significance of this find-
ing is that it confers a more than 50-fold risk of pro-
gression to esophageal adenocarcinoma. Beyond this,
many of the details of the natural history of Barrett’s
esophagus remain an enigma. For example, it has been
suggested that Barrett’s esophagus develops quickly to
its full extent, with little subsequent increase in length.1
This suggestion was based on data from patients with
only long segments of Barrett’s mucosa within the tubu-
lar esophagus (ie, ‡ 3 cm). It is now accepted that
intestinal metaplasia occurs in segments of cardiac-type
mucosa that are less than 3 cm in length and that intesti-
nal metaplasia can occur in small amounts of cardiac-
B arrett’s esophagus is a complication of gastroe-sophageal reflux disease characterized by the pres-
ence of intestinal metaplasia in an esophagus lined by
Objective: The purpose of this study was to assess whether the extent of
intestinal metaplasia is related to the severity of the gastroesophageal
reflux disease. Methods: A total of 556 consecutive patients with symp-
toms suggestive of foregut disease had upper gastrointestinal endoscopy
with extensive biopsies from the gastroesophageal junction and the
esophagus. All patients had esophageal motility and 24-hour pH moni-
toring. In 411 patients, cardiac-type mucosa was identified; in 147
patients, the cardiac-type mucosa showed intestinal metaplasia. They
were divided into 3 groups based on the extent of intestinal metaplasia
commonly seen clinically: long segments (>3 cm), short segments (<3
cm), and limited to the gastroesophageal junction. The duration of
symptoms, the status of the lower esophageal sphincter, the degree of
esophageal acid exposure, and the time to clear a reflux episode were
assessed in each group. Results: The presence of intestinal metaplasia in
cardiac-type mucosa was associated with the hallmarks of gastroe-
sophageal reflux disease. The extent of intestinal metaplasia correlated
strongly with the degree of esophageal acid exposure (r = 0.711; P <
.001) and inversely with the lower esophageal sphincter pressure (r =
0.351; P < .001) and length (r = 0.259; P = .002). Patients with a long seg-
ment of intestinal metaplasia (>3 cm) had longer duration of symptoms
(16 years) than those patients with a segment of intestinal metaplasia
less than 3 cm (10 years; P = .048) or those patients with intestinal meta-
plasia limited to the gastroesophageal junction (10 years; P = .01).
Conclusion: The extent of intestinal metaplasia, that is, Barrett’s esopha-
gus, is related to the status of the lower esophageal sphincter and the
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type mucosa just below the squamous epithelium of an
endoscopically normal-appearing gastroesophageal
junction.2-4 These observations justify a reevaluation of
the commonly held belief that Barrett’s esophagus,
once developed, does not progress.
We have recently shown that the presence of cardiac-
type mucosa at the gastroesophageal junction is usual-
ly associated with an inflammatory infiltrate and is an
early sign of gastroesophageal reflux disease.5 It has
been further shown that, as the length of the cardiac-
type mucosa increases, there is a progressive deteriora-
tion of the lower esophageal sphincter pressure and an
increase in esophageal acid exposure.6-8 Recently, it
has been recognized that segments of cardiac-type
mucosa limited to the gastroesophageal junction can
show intestinal metaplasia on biopsy.2-4 The histologic
condition of these biopsy specimens is identical to
biopsy specimens obtained from patients with Barrett’s
esophagus who have longer segments of intestinal car-
diac-type mucosa. Because of the rather high frequen-
cy of this finding, its significance has been questioned.
The aim of this study was to determine whether
intestinal metaplasia arising in cardiac-type mucosa,
regardless of whether it is limited to the gastroe-
sophageal junction or extending into the esophagus, is
associated with the hallmarks of gastroesophageal
reflux disease and, if so, whether the extent of intesti-
nal metaplasia is dependent on the severity of the func-
tional abnormality identified with this disease. If this
were so, it would suggest that the formation of Barrett’s
esophagus is a progressive process. It starts with the
intestinalization of endoscopically occult segments of
cardiac-type mucosa arising at the gastroesophageal
junction. With increasing severity of reflux disease, the
intestinalized segment may extend into the esophagus
within the region of the lower esophageal high-pressure
zone and eventually, when the antireflux barrier is lost,
further up into the tubular esophagus.
Patients and methods
Patient population. Between July 1991 and December
1997, 556 consecutive patients (336 male and 234 female;
median age, 53.4 years; range, 18 to 89 years) were examined
for symptoms suggestive of foregut disease. Symptoms con-
sisted of heartburn, regurgitation, dysphagia, noncardiac
chest pain, epigastric pain or those suggestive of aspiration
such as recurrent pneumonia, wheezing, and persistent
cough. Patients with named motility disorders and a history
of previous gastric or esophageal operation were excluded.
All patients underwent upper endoscopy with biopsy, stan-
dard esophageal manometry, and 24-hour esophageal pH
monitoring.
Stationary motility. Standard stationary motility was per-
formed after an overnight fast. Lower esophageal resting
pressure was measured at the respiratory inversion point, as
previously described.9 The 3 criteria used to determine the
structural integrity of the lower esophageal sphincter (resting
pressure, overall length, and abdominal length) were calcu-
lated from the mean of 5 measurements. A structurally defec-
tive sphincter was defined by the presence of 1 or more of the
following conditions: a resting pressure of less than 6 mm Hg,
an overall sphincter length of less than 2 cm, or an abdominal
length of less than 1 cm.
Ambulatory 24-hour esophageal pH monitoring.
Esophageal pH monitoring was performed with a glass elec-
trode (Ingold Inc, Urdorf, Switzerland) placed 5 cm above the
upper border of the manometrically defined lower esophageal
sphincter. Medications were discontinued 72 hours before
testing, except for omeprazole, which was discontinued at
least 2 weeks earlier. Esophageal pH was recorded on a
portable digital data recorder and was analyzed as previously
described.10 Patients with esophageal pH less than 4.0 for
more than 4.4% of the monitored time were classified as hav-
ing increased esophageal acid exposure.10
Endoscopy. All patients underwent upper gastrointestinal
endoscopy with biopsy. The gastroesophageal junction was
identified by the proximal extent of the gastric rugae. The
squamocolumnar junction was identified by the change from
pink-appearing glandular mucosa to the white pearly appear-
ing squamous mucosa. All patients had 3 to 6 biopsy speci-
mens obtained from the gastroesophageal junction. Patients
with an irregular squamocolumnar junction that coincided
with the gastroesophageal junction had 2 or more biopsy
specimens obtained from the tongues of glandular mucosa
extending into the esophagus. In patients whose squamo-
columnar junction was separated from the gastroesophageal
junction, biopsy specimens were obtained from 4 quadrants
at 2-cm intervals throughout the length of the separation. The
locations of the gastroesophageal junction, the squamo-
columnar junction, and each biopsy specimen were recorded
in centimeters from the incisor teeth.
Histologic evidence. All biopsy specimens underwent rou-
tine fixation and staining with hematoxylin and eosin and
were analyzed for the type and the condition of the epitheli-
um. Gastric fundic mucosa was characterized by glands that
contained parietal and chief cells and was devoid of mucous
cells, except those lining the surface and foveolar region.
Cardiac-type or columnar mucosa was characterized by a
columnar epithelium with glands composed entirely of
mucous cells without any parietal or chief cells. Inflam-
mation of cardiac-type mucosa was diagnosed by the pres-
ence of eosinophil or plasma cell infiltration of the lamina
propria and hyperplasia of the mucous cells in the foveolar
region. Specialized intestinal metaplasia was identified by the
presence of well-defined goblet cells within columnar epithe-
lium. The presence of goblet cells was confirmed by a posi-
tive staining with alcian blue at pH 2.5.
Definition of study groups. The patients were divided into
3 groups on the basis of the extent of cardiac-type mucosa
with intestinal metaplasia recently reported to be commonly
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seen in the endoscopy suite.4 Those patients with no endo-
scopically apparent cardiac-type mucosa above the gastroe-
sophageal junction but in whom intestinal metaplasia in car-
diac-type mucosa was found in biopsy specimens from just
below the squamocolumnar junction were classified as hav-
ing intestinal metaplasia limited to the gastroesophageal
junction. Patients with intestinal metaplasia and a complete
or partial separation of less than 3 cm between the gastroe-
sophageal and squamocolumnar junction were classified as
having short-segment intestinal metaplasia. Long-segment
intestinal metaplasia was diagnosed when the separation
between the gastroesophageal and the squamocolumnar junc-
tion was 3 cm or more.
Statistics. Data are reported as medians and interquartile
ranges unless otherwise stated. The c 2 and Fisher’s exact tests
were used to compare proportions. Continuous data was com-
pared in the 3 groups with the Kruskal-Wallis test.
Comparisons between individual groups were performed
with the Mann-Whitney U test.
Results
Overall, 411 of the 556 patients had cardiac-type
mucosa on biopsy specimens of their esophagus or gas-
troesophageal junction. Of these, 147 patients (35%)
had intestinal metaplasia. Fig 1 shows that the preva-
lence of intestinal metaplasia occurring within cardiac-
type mucosa increased progressively in patients
grouped according to the extent of the cardiac mucosa.
Demographics of the 3 groups are shown in Table I.
Patients with segments of intestinal cardiac-type
mucosa 3 cm or greater had significantly longer dura-
tion of reflux symptoms than those patients with seg-
ments shorter than 3 cm or those patients in whom it
was limited to the gastroesophageal junction.
Table II shows the hallmarks of gastroesophageal
reflux disease in the 3 patient groups. There was a pro-
gressive reduction in the median lower esophageal
sphincter pressure and abdominal length in the 3
patient groups. Further, when each patient was consid-
ered individually, there was an inverse correlation
between the extent of intestinal cardiac-type mucosa
and their lower esophageal sphincter pressure (Fig 2)
Fig 1. The prevalence of intestinal metaplasia occurring within cardiac-type mucosa of varying extents: limited to
the gastroesophageal (GE) junction, involving short (<3 cm) and long (‡ 3 cm) segments of the esophageal body.
Table I. Demographic data in patients with varied lengths
of cardiac-type mucosa with intestinal metaplasia
Length of cardiac type of mucosa 
with intestinal metaplasia
Limited to the Involving Involving 
gastroesophageal <3 cm of the ‡ 3 cm of the 
Demographic junction esophagus esophagus 
No. of patients 34 44 68
Male/female 22:12 29:15 53:15
Age (y) 53 52 54
Range 22-78 34-74 24-83
IQR 42-60 44-62 43-62
Duration of 10 10† 16*
symptoms (y)
Range 1-30 1-48 1-48
IQR 4-14 5-17 9-20
IQR, Interquartile range; y, years.
*P < .05 vs all other groups.
†P = .05 vs limited to gastroesophageal junction.
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and abdominal length (Fig 3). The extent of intestinal
cardiac-type mucosa with intestinal metaplasia also
increased as the number of defective components of the
lower esophageal sphincter in each patient increased
(Fig 4).
Also, the clearance function of the esophageal body
decreased in the 3 patient groups (Table II). This was
reflected by an increase in the median number of reflux
episodes greater than 5 minutes in duration and the
median duration of the longest reflux episodes. These
markers of reduced clearance function were associated
with significantly poorer esophageal contraction ampli-
tudes in the patients with short (<3 cm) and long (‡ 3
cm) segments of intestinal cardiac-type mucosa com-
pared with those with involvement limited to the gas-
troesophageal junction.
As would be expected from the loss of the lower
esophageal sphincter function, the extent of intestinal
cardiac-type mucosa was also related to the esopha-
geal acid exposure (Table II). There was a progressive
increase in the median acid exposure in the 3 patient
groups as measured by the percentage of time the pH
was less than 4 and the number of reflux episodes.
When each patient was considered individually, there
was a strong direct correlation between the length of
cardiac mucosa with intestinal metaplasia and the per-
centage of time that their esophagus was exposed to
pH less than 4 (Fig 5).
An important observation was that intestinal meta-
plasia was always found in the proximal portion of the
cardiac-type mucosal segment, but its presence varied
distally (ie, it was not found distally in 22 of 44 of the
patients [50%] with a short [<3 cm] and 41 of 68 of the
patients [60%] with a long segment [‡ 3 cm]).
Discussion
The results of the present study support the concept
that the presence of intestinal metaplasia in cardiac-type
mucosa, regardless of its extent, represents Barrett’s
esophagus, because these patients exhibit the hallmarks
of gastroesophageal reflux disease, including decreased
lower esophageal sphincter pressure and length and
increased esophageal acid exposure.11 The extent of the
intestinal mucosa seemed to increase with progressive
deterioration of the antireflux barrier. Compromised
sphincter function may result from inflammatory
changes in the muscularis propria caused by increased
esophageal acid exposure.5 With time the lower
esophageal sphincter deteriorates, allowing the
esophageal body to be exposed to gastric juice. Cardiac-
type mucosa with intestinal metaplasia can form in the
tubular esophagus as a result of the increased exposure
to gastric juice. The inflammation caused by this
process results in the loss of esophageal body contrac-
tility classically seen in patients with long segments of
Barrett’s esophagus.12 Intuitively, it appears logical that
long segments of intestinal metaplasia are short before
they become long. Fontolliet and Monnier (Departments
Table II. Functional characteristics of gastroesophageal reflux disease in patients with varied lengths of cardiac-type
mucosa with intestinal metaplasia
Length of cardiac type of mucosa with intestinal metaplasia
Limited to the Involving Involving 
gastroesophageal <3 cm of the ‡ 3 cm of the 
Demographic junction esophagus esophagus 
Lower esophageal sphincter
Resting pressure (mm Hg) 7.2 (5.5-13.3) 6.4 (3.6-10.2) 3.8 (2.0-6.2)*
Overall length (cm) 2.2 (1.8-3.0) 2.1 (1.4-3.5) 1.8 (1.2-2.6)†
Abdominal length (cm) 1.0 (0.4-1.4) 0.9 (0.2-1.6) 0.4 (0.2-1.0)*
Prevalence defective lower esophageal sphincter (%) 52.9 65.9 94.1*
Esophageal body
Distal amplitude (mm Hg) 79 (53-117) 61 (36-79)† 51 (35-76)†
No. of reflux episodes >5 min 2 (1-4) 5 (2-7)† 7 (4-18)*
Duration of longest episode (min) 10.0 (5-21) 17.5 (12-25)† 28 (12-52)*
Esophageal acid exposure
Time pH < 4.0 (%) 5.8 (3.9-8.2) 8.4 (6.1-14.0)* 16.5 (11.2-29.9)*
Prevalence abnormal exposure (%) 64.7 86.4† 92.6†
No. of reflux episodes 53 (19-91) 81 (57-139)† 197 (118-267)*
Values expressed as medians and IQR, except for prevalence data.
*P < .05 vs all other groups.
†P < .05 vs limited to the gastroesophageal junction.
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of Pathology and Head and Neck Surgery, CHUV,
University of Lausanne, Lausanne Switzerland.
Personal communication; letter received September 18,
1998.) have observed 120 patients with Barrett’s esoph-
agus over a median of 60 months; in 29 patients, they
measured a progression from 5.6 cm (3-15 cm) to 9.2
cm (5-20 cm). All of these patients had lengths of 3 cm
or greater. To our knowledge, similar studies on lengths
shorter than 3 cm have not been reported. It may be that
it is endoscopically more difficult to measure increases
in the length of shorter segments.
In contrast to this stepwise hypothesis is the com-
monly accepted belief that Barrett’s esophagus devel-
ops rapidly to its full extent with no subsequent change.
This concept is based largely on the report of Cameron
and Lomboy,1 whose study consisted entirely of
patients with an esophageal columnar lining of 3 cm or
more. They observed 21 patients with Barrett’s esoph-
agus for a mean of 7.3 years. The average initial length
of columnar epithelium was 8.29 cm, and the final
length was 8.33 cm, not significantly different. Their
strongest evidence that the extent of Barrett’s esopha-
Fig 2. The relationship between the extent of cardiac-type mucosa with intestinal metaplasia (IM) and resting
pressure of the lower esophageal sphincter (LESP) on standard esophageal manometry.
Fig 3. The relationship between the extent of cardiac-type mucosa with intestinal metaplasia (IM) and lower
esophageal sphincter (LES) abdominal length on standard esophageal manometry.
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gus does not change significantly over time was that the
mean length of columnar epithelium was similar in all
age groups. These findings would be expected because
patients with long segments of columnar lining uni-
formly have profound defects in the antireflux mecha-
nisms that results in very high esophageal exposure to
gastric contents.12 Such patients represent a stage of
disease in which further deterioration of the antireflux
mechanism or increases in esophageal exposure to gas-
tric juice would not be expected to occur.
Rather than implicating the sudden occurrence and
unchanging extent of Barrett’s metaplasia, their find-
ings can be explained by the normal gradient between
the positive pressure in the stomach and the negative
pressure in the thoracic esophagus. When the antireflux
mechanism completely deteriorates, gastric juice flows
Fig 4. The relationship between the extent of cardiac-type mucosa with intestinal metaplasia (IM) and degree of
lower esophageal sphincter (LES) competency. Values of each subject are plotted; the horizontal line denotes the
mean of each group.
Fig 5. The relationship between the extent of cardiac-type mucosa with intestinal metaplasia (IM) and the per-
centage of time spent below pH 4.0 on 24-hour esophageal pH monitoring.
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to the point of lowest esophageal pressure in the
midthoracic esophagus.13 Under these conditions,
intestinalized cardiac-type mucosa may develop to this
point with no apparent subsequent change in length.
The most controversial issue is whether the intesti-
nalized cardiac-type epithelium found at the gastroe-
sophageal junction represents the Barrett’s metaplasia
seen in reflux disease.14 In part, this controversy exists
because most authors base the diagnosis of intestinal
metaplasia of the cardia on the location of the biopsies,
that is, the anatomic gastric cardia, which infrequently
harbors cardiac-type mucosa, rather than the type of
underlying mucosa in which the intestinal metaplasia
occurs.15,16 Further, intestinal metaplasia arising in
fundic or antral mucosa has been associated with
Helicobacter pylori infection, and it would seem rea-
sonable that the same would hold true for the car-
dia.17-19 It has been shown, however, that intestinal
metaplasia in cardiac-type mucosa is not associated
with the presence of H pylori or other gastric patholo-
gy; rather, it is associated with gastroesophageal reflux
disease.5,8 If intestinal metaplasia of cardiac-type
mucosa in patients with an endoscopically normal-
appearing distal esophagus is a manifestation of gas-
troesophageal reflux, then it follows that it most likely
represents endoscopically inapparent segments of
Barrett’s metaplasia. Further, this observation is in
keeping with the rapid and parallel increase of adeno-
carcinoma of the esophagus and the gastroesophageal
junction, that is distinct from that of the stomach and is
a known complication of Barrett’s esophagus.20,21
The observation that not all patients with cardiac-
type mucosa experience the development of intestinal
metaplasia suggests that the development of Barrett’s
esophagus is a 2-step process. In the first step, car-
diac-type mucosa forms as a normal response of the
squamous epithelium to acid exposure.5,22,23 Intestinal
metaplasia develops in time under the proper luminal
condition and stimulus as a second step. Indeed, in
children in whom the esophagus is lined by columnar
epithelium, intestinal metaplasia rarely occurs before
the age of 5 years, and clinical studies have shown a
time lag of 5 to 7 years for the development of intesti-
nal metaplasia in adults.24-26 Patients with long seg-
ments of cardiac-type mucosa are more likely to show
intestinal metaplasia, because based on the duration
of symptoms the process has been going on for a
longer time (Table I). In support of the 2-step hypoth-
esis, Hamilton and Yardley27 reported the development
of Barrett’s mucosa in the esophagus above the anas-
tomosis in 3 patients after esophagogastrectomy. In 2
of these patients, they documented progression from
squamous epithelium to cardiac mucosa and subse-
quently intestinal metaplasia over 6.3 and 10 years.
The observation that intestinal metaplasia consistently
occurs in the proximal portion of the cardiac-type
mucosal segment can be explained by the luminal pH
exposure. The proximal portion of the cardiac-type
mucosal segment is most likely to be exposed to the pH
3 to 5 because of dilution and neutralization of the
refluxed gastric acid by saliva. Exposure of columnar
epithelial cells to this pH range has been shown to
encourage the phenotypic expression of intestinaliza-
tion. In contrast, exposure to duodenal mucosa to an
acid pH reduces the expression of intestinalization.
This is in accordance with the observation that the
small intestinal brush border is lost after exposure to
acetic acid.28 This would account for the observation
that intestinal metaplasia is less commonly in the more
distal portion of the Barrett’s segment because this
mucosa is more likely to be exposed to the acidic pH of
refluxed gastric juice that has not been diluted or neu-
tralized by saliva.
On the basis of our findings, we hypothesize that
Barrett’s esophagus spreads progressively in a stepwise
fashion. Initially, intestinal metaplasia may develop in
endoscopically indistinguishable segments of cardiac-
type mucosa at the gastroesophageal junction. With
weakening of the lower esophageal sphincter and con-
tinued acid exposure, intestinalized cardiac-type
mucosa develops within the distal 3 cm of the esopha-
gus. With time and the loss of the sphincter, the process
is extended higher into the esophagus.
We conclude that the development of Barrett’s esoph-
agus is not a static but a dynamic phenomenon and that
the extent of intestinal metaplasia is determined by the
severity of the functional abnormalities identified with
gastroesophageal reflux disease.
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Discussion
Dr Victor F. Trastek (Rochester, Minn). Adenocarcinoma
of the esophagus is a deadly disease that is increasing in inci-
dence and is related to Barrett’s esophagus in almost all
cases. The best way to improve survival in this dismal disease
is to detect and treat it early. To do this, we must understand
the pathophysiology of the entire process, the first portion of
which is the development of the columnar-lined esophagus,
or Barrett’s esophagus. 
Although this is most likely the result of acid and duodenal
content reflux, it is unclear exactly how the Barrett’s mucosa
develops in a patient over time. Dr Öberg and his colleagues
would suggest from their work that the columnar epithelium
develops in a creeping fashion, progressing over time in the
patient. This assumption is based on the fact that the longest
length of columnar epithelium was found in the patients with
the most severe gastroesophageal reflux disease, those who
had had the worst functional parameters. Also lending sup-
port to this assumption was the fact that intestinal metaplasia
was usually found at the most distal end of the Barrett’s
process. 
I applaud Dr Öberg and his colleagues in lending more infor-
mation to the pathophysiology and development of Barrett’s
esophagus, but I am not convinced that they have proved the
progression theory. To truly prove progression, one most see
increasing length sampled over time in a particular patient.
This study shows differences in length at 1 point in time com-
paring 1 patient to another. The argument would have been
much more compelling had the data points been sampled over
a period of time that showed that the length of the Barrett’s
increased as the severity of the disease progressed. 
It is still unclear from this study, by looking at just 1 point
in time, whether the increased severity of disease caused the
increased length. On the other hand, maybe the development
of Barrett’s esophagus in some way affects how the esopha-
gus functions and therefore those patients have the most
severe parameters of function. So, I do not think we know yet
whether the cart comes before the horse or the other way
around.
In your patient group, do you have any information sam-
pling a single patient over a period of time in which you
could show us that increasing severity of disease was linked
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to increasing length of Barrett’s disease? If progression is
indeed the way this Barrett’s mucosa develops, why do not all
patients eventually end up with a total esophagus full of
Barrett’s mucosa?
Dr Öberg. Regarding the first question, none of the
patients in this study were assessed more than once, so we
have no longitudinal data. I completely agree with you that
the best way of assessing this issue is to have longitudinal
long-term studies of patients with short segments of Barrett’s
esophagus. However, this is very difficult to do because to
study the natural history of Barrett’s esophagus you need to
leave the patients untreated, and I do not think we can do that. 
You next asked why all patients do not progress to 8 cm of
Barrett’s esophagus. I believe that this does not happen
because gastroesophageal reflux is a spectrum of diseases in
which the severity varies. I think we can show, based on the
data from this study, that the extent of Barrett’s esophagus is
determined by the severity of reflux disease. All patients do
not experience the development of end-stage reflux disease
and that is why not all patients experience the development of
Barrett’s esophagus to its full extent.
Dr Claude Deschamps (Rochester, Minn). Do you survey
those patients who have limited Barrett’s at the cardia differ-
ently than the patients who have more extensive Barrett’s?
For example, if your program does check on patients every
year, do you survey those patients less often? 
Second, when you perform cardiac procedures on these
patients, do you charge as a cardiac surgeon?
Dr Öberg. In response to your first question, I do believe
that these patients have an increased risk of the development
of adenocarcinoma at the gastroesophageal junction.
However, because intestinal metaplasia of the gastroe-
sophageal junction is a frequent finding and the risk of the
development of adenocarcinoma in these patients is
unknown, we do not know whether they benefit from surveil-
lance. Because we are interested in research and eager to
know more about this disease, we offer these patients sur-
veillance. I believe that until we know more about the effec-
tiveness and benefits of surveillance, these patients should
undergo surveillance only in controlled studies. The frequency
with which this should be done is unknown.
To answer your second question, no, we do not charge for
cardiac procedures.
Dr Andre C. H. Duranceau (Montreal, Quebec, Canada). If
you find intestinal metaplasia in the proximal wall of the stom-
ach, you call it intestinal metaplasia in the stomach. Why do
you try to tag it on the esophagus when it is under the cardia?
Dr Öberg. This is a very important concept, and I am
happy you asked this question because it is easy to get con-
fused when you read the conflicting reports in the literature.
Unlike most recent reports on this subject, the biopsy speci-
mens in this study were obtained at the gastroesophageal
junction, just below the squamocolumnar junction, and not
from the stomach. Many authors report on biopsy specimens
obtained from the anatomic gastric cardia, which is part of
the stomach, and find that the presence of intestinal metapla-
sia is associated with H pylori infection. We believe that this
is not the way to study changes occurring in the transition
between the esophagus and the stomach, because when you
biopsy the anatomic gastric cardia you infrequently find car-
diac-type mucosa, but you do find gastric fundic-type
mucosa. We base our findings concerning carditis and intesti-
nal metaplasia on the underlying mucosa rather than the loca-
tion of the biopsy specimen. Inflammation and intestinal
metaplasia in the gastric fundic mucosa is not likely related
to reflux, because fundic mucosa is believed to be resistant to
acid-peptic digestion but rather associated with H pylori
infection. However, when found, cardiac-type mucosa is
almost always inflamed, and as we have shown in previous
articles it is associated with the presence of reflux.
Dr David W. Myers (Annapolis, Md). Did you collect
information on the severity of the metaplasia, high versus low
grade, as well as the extent? If you did collect it, did you find
that it did correlate as well with the severity of gastro-
esophageal reflux just as the extent of the Barrett’s correlated?
Dr Öberg. Within these 556 patients, there were 9 patients
with low-grade dysplasia but no patients with high-grade dys-
plasia. Low-grade dysplasia occurred in all lengths of intesti-
nal metaplasia, including those limited to the gastro-
esophageal junction. There was no difference in esophageal
acid exposure between patients with and without dysplasia,
but we have previously shown that there is an association
with complicated Barrett’s esophagus, including dysplasia,
and the presence of duodenogastroesophageal reflux.
However, this was not part of the present study.
Dr David J. Sugarbaker (Boston, Mass). You correlated
rather nicely the amount of reflux with the extent of metapla-
sia. Do you have any data on long-term use of H2 blockers or
omeprazole (Prilosec) or other antacid therapy? Many patients
these days are on long-term therapy, and I wonder if you could
comment, from a demographic standpoint, about whether any
of this has an effect on the development of metaplasia.
Dr Öberg. We know that almost all of these patients were
treated with proton pump inhibitors and H2 blockers; whether
that treatment affected the formation of Barrett’s esophagus is
not known. However, we have shown that patients with
Barrett’s esophagus do have an increased prevalence of duo-
denogastroesophageal reflux. Treatment with proton pump
inhibitors suppresses gastric acid secretion and results in ele-
vated gastric pH, which may lead to bacterial overgrowth and
deconjugation of the bile acids. These bile acids have been
shown to be more harmful and may possibly affect the for-
mation of Barrett’s metaplasia. We are currently studying
this, but to date, we have no definite data.
